Clinigen Share Price (CLIN)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Clinigen Group	LSE:CLIN	London	Ordinary Share	GB00B89J2419	ORD 0.1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+9.00p	+0.86%	1,061.00p	1,057.00p	1,059.00p	1,068.00p	1,036.00p	1,047.00p	520,620	16:35:10

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	339.9	15.9	11.9	89.2	1,221.86

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), Port Erin (PEBI), Valirx (VAL)

Clinigen (CLIN) Latest News (16)

Clinigen News

Date	Time	Source	Headline
22/9/2017	16:05	UKREG	Putnam Investments Form 8.3 - Clinigen Group plc
22/9/2017	15:20	UKREG	BlackRock Group Form 8.3 - Clinigen Group plc
22/9/2017	15:04	UKREG	AXA Investment Managers S.A. Form 8.3 - Axa Investment Managers : Clinigen..
22/9/2017	15:00	UKREG	Sand Grove Capital Management LLP Form 8.3 - Clinigen Group PLC
22/9/2017	14:27	UKREG	Octopus Investments Ltd Octopus Investments Ltd : Form 8.3 - Clinigen Group..
22/9/2017	14:17	UKREG	Schroders PLC Form 8.3 - [Clinigen Group plc]
22/9/2017	13:28	UKREG	GAM Holding AG Form 8.3 - Clinigen Group plc
22/9/2017	13:27	UKREG	GAM Holding AG Form 8.3 - Clinigen Group plc
22/9/2017	13:20	UKREG	GAM Holding AG Form 8.3 - Clinigen Group plc
22/9/2017	13:16	UKREG	GAM Holding AG Form 8.3 - Clinigen Group plc

More Clinigen News

Clinigen Takeover Rumours

Clinigen (CLIN) Share Charts

1 Year Clinigen Chart

1 Month Clinigen Chart

Intraday Clinigen Chart

Clinigen (CLIN) Discussions and Chat

Clinigen Forums and Chat

Date	Time	Title	Posts
16/8/2017	12:12	Clinigen - Speciality Pharmaceuticals	846
07/1/2015	16:38	Clinigen - solid looking growth stock	31

Add a New Thread

Clinigen (CLIN) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Clinigen trades in real-time

Clinigen (CLIN) Top Chat Posts

Date	Subject
24/9/2017 09:20	Clinigen Daily Update: Clinigen Group is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker CLIN. The last closing price for Clinigen was 1,052p. Clinigen Group has a 4 week average price of 1,014p and a 12 week average price of 837p. The 1 year high share price is 1,149p while the 1 year low share price is currently 674p. There are currently 115,160,923 shares in issue and the average daily traded volume is 685,945 shares. The market capitalisation of Clinigen Group is £1,221,857,393.03. Read Full Thread Reply
17/4/2017 02:21	shaker44: Just watch out for continually heavy selling from Andrew Leaver and connections as they run down their founding stake.I got in and out as the share price takes 2 steps forward and 2-3 steps back. When the sell off is done it should be a good investment. All imo. Read Full Thread Follow Reply
09/6/2016 10:22	arc en ciel: Plus there's news of another drug to distribute. Looks like a good addition to the portfolio: http://uk.advfn.com/stock-market/london/clinigen-CLIN/share-news/Clinigen-Group-plc-New-MA-program-with-Basilea/71690318 Read Full Thread Follow Reply
13/5/2016 08:23	lomax99: Stock oversold. IC comment: Pharmaceutical group Clinigen (CLIN) gained support from investors when it first joined Aim in 2012, hailed for its position in a rapidly growing market and its highly experienced management team. Despite these factors remaining significant bull points, in the past few years the share price has failed to keep up the same momentum, and in recent months has seen a notable drop-off. This may in part be due to a slow first half caused by a large order for its key drug, Foscavir, slipping into the second six months, along with two big managed access contracts finishing. Also there appears to be some concern surrounding integration costs associated with two major acquisitions made in 2015. However, we feel these concerns have been overdone and see the recent share price weakness as an excellent opportunity to buy into the company's long-term growth. Idis and Link Healthcare, the two companies acquired in 2015, have improved Clinigen's business mix by reducing its reliance on erratic revenues from its clinical trials business - 18 per cent of first-half gross profit. Idis operates in two divisions, managed access and global access, which aim to provide physicians with treatments that are not available in their own country. These two divisions together contributed £19.1m of gross profits in the six months to December 2015, up from just £2.9m in the comparable period of the prior year. Link Healthcare was acquired in October and contributed £2.7m of revenue in just two months. Link provides commercial access to specialist medical technology products, specifically in Asia, Africa and Australasia, which expands both Clinigen's product range and its geographical reach. While integration costs associated with these acquisitions are likely to persist this year, Idis and Link are already boosting group earnings and brokers are forecasting significant upside in revenue and profits. The acquisitions were largely funded by extended banking facilities, which has stretched net debt to £82m. However, Clinigen is highly cash generative and net debt is forecast to fall to £23m by 2017, according to broker Numis. Specialist pharmaceuticals (SP) remains the largest contributor and accounted for almost a third of first-half gross profit. The group buys poorly managed drugs from big pharmaceutical companies and "revitalises" them, with the aim of doubling turnover by improving access to supply. The misconduct by Canadian company Valeant may have soured some investors' perception of such businesses, but Clinigen has a strong reputation. Foscavir, for the treatment of diseases associated with HIV, is the group's leading product. When it was acquired in 2010 it made £4.3m sales and in the most recent financial results it contributed £23m of revenue. While an order delay hit first-half performance, prospects remain good and Clinigen has developed a new 250ml bag, which it plans to replace the current glass bottle presentation of the drug. The bag is likely to widen Foscavir margins, enhance Clinigen's market share and, hopefully most notably, hold off generic competition. The company is trying to reduce its reliance on Foscavir by buying and developing new drugs, and added a sixth treatment, oncology support drug Totect, to its stable in March. In the first half, Clinigen's newer share price drugs increased sales by 74 per cent, taking their contribution to more than two-fifths of the division's total. Clinigen continues to demonstrate an impressive ability to revitalise drugs and is using acquisitions to branch out into new growth areas. Broker Numis believes the company can produce mid-double-digit annual earnings growth out to 2018, or more than 20 per cent a year, with the help of further acquisitions. That potential looks significantly undervalued by the shares' rating of just 15 times 2016 earnings. Buy. Read Full Thread Follow Reply
02/3/2016 10:46	3rd eye: Clinigen Group PLC 57.4% Potential Upside Indicated by Peel Hunt Posted by: Katherine Hargreaves 2nd March 2016 Clinigen Group PLC using EPIC/TICKER code LON:CLIN had its stock rating noted as ‘Reiterates217; with the recommendation being set at ‘BUY’ this morning by analysts at Peel Hunt. Clinigen Group PLC are listed in the Health Care sector within AIM. Peel Hunt have set their target price at 1000 GBX on its stock. This is indicating the analyst believes there is a potential upside of 57.4% from the opening price of 635.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 3.77805799999999 points and decreased 45 points respectively. Clinigen Group PLC LON:CLIN has a 50 day moving average of 652.97 GBX and a 200 day moving average of 670.64 GBX. The 1 year high for the share price is 773.5 GBX while the 52 week low for the share price is 495 GBX. There are currently 114,740,899 shares in issue with the average daily volume traded being 383,240. Market capitalisation for LON:CLIN is £731,358,378 GBP. Clinigen Group PLC is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP). Read Full Thread Follow Reply
13/11/2015 12:03	arc en ciel: Marine Boy: Don't be too hard on yourself. Perhaps this will help lift your spirits- SCSW said in its October edition, with the share-price at 705p: "Starting to look like a monster. Keep holding". Read Full Thread Follow Reply
05/8/2015 13:44	cfro: Share price getting steeper by the day...:0)) Read Full Thread Follow Reply
18/9/2014 16:43	mechanical trader: Clinigen Group plc Clinigen Launch Antibiotic, Vibativ in Europe Date : 18/09/2014 @ 16:15 Source : RNS Non regulatory Stock : Clinigen (CLIN) Quote : 463.75 2.0 (0.43%) @ 16:20 HOME » LSE » LSE » Clinigen share price Clinigen Group plc Clinigen Launch Antibiotic, Vibativ in Europe Share On Facebook Print Alert TIDMCLIN Clinigen Group plc 18 September 2014 Clinigen Group launches New First-in-Class Antibiotic VIBATIV(R) (telavancin) for MRSA related Hospital-Acquired Pneumonia across Europe Burton-on-Trent, UK - 18 September 2014 - Clinigen Group plc ('Clinigen' or the 'Group') (AIM: CLIN), the specialty global pharmaceutical company, today announced that the new first-in-class bactericidal, once-daily, injectable antibiotic VIBATIV(R) (telavancin), is now available to prescribe in Europe for the treatment of adults with nosocomial pneumonia (also known as hospital acquired pneumonia - HAP), including ventilator associated pneumonia (VAP), known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA) when other alternatives are not suitable. In March 2013, Clinigen, in-licensed V IBATIV(R) from Theravance, Inc. for commercialization in Europe, however, at that time the European Marketing Authorisation for the drug was suspended due to stopped operations at the previous manufacturer. Clinigen worked closely with a new contract manufacturer and the relevant European authorities to have the suspension lifted. The European Commission (EC) confirmed this in March 2014 enabling Europe-wide, licensed supply to commence. This will be the first time the licensed product will be available in Europe. VIBATIV(R) is an innovative treatment for HAP, the most common cause of death among infections acquired in a hospital setting, in that it offers a dual mechanism of action enabling it to kill even drug resistant strains of Staphylococcus aureus.([1]) The drug's dual mechanism of action means that even a strain resistant to one of the mechanisms of action may still be affected by the other mechanism, suggesting that VIBATIV(R) may be less prone to resistance than other antibiotics. HAP caused by MRSA is a considerable unmet need, recognised as a public health priority in the EU. MRSA is estimated to cost EUR380 million every year in extra hospital costs.([2]) As a result of these high costs, both economic and human, there is increasing demand for new tools to combat infections caused by drug-resistant bacterial strains and the availability of new antibacterial agents is recognised as playing an important role in treating MRSA. 30-70% of patients who acquire HAP currently die despite early and appropriate treatment, and the condition places a large burden on healthcare systems.([3]) There is a limited choice of licensed antibiotic therapies able to treat HAP/VAP caused by MRSA and therefore this launch provides an important, alternative, effective agent in the fight against the growing problem of resistance by bacteria. "HAP caused by MRSA is often more serious and difficult to treat than similar infections with more drug susceptible strains," said Professor Matteo Bassetti, Professor of Infectious Diseases, School of Medicine and Postgraduate School of Infectious Diseases, University of Udine, Italy. "We are increasingly seeing bacteria acquire resistance to antibiotics previously considered last resort treatments; we need more options to treat these extremely serious infections. The widespread availability of a new and effective antibiotic such as VIBATIV(R) is therefore very good news for Europe." "The emergence of so-called 'super bugs' and increasing resistance among microbes to existing antibiotics has been recognised internationally as a major clinical challenge," said Peter George, Group Chief Executive Officer at Clinigen Group plc. "We are therefore extremely proud to be making this potentially life-saving medicine available across Europe for people who may have no other suitable option to fight a life-threatening infection." - Ends - About VIBATIV(R) (telavancin) VIBATIV(R) is a bactericidal, once-daily, injectable lipoglycopeptide antibiotic with a dual mechanism of action whereby VIBATIV(R) both inhibits bacterial cell wall synthesis and disrupts bacterial cell membrane function. VIBATIV(R) is approved in the United States (US) for the treatment of adult patients with (i) complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including Staphylococcus aureus, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains, and (ii) hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable. In September 2011, the European Commission granted Marketing Authorization for VIBATIV(R) for the treatment of nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by MRSA when other alternatives are not suitable. VIBATIV(R) was discovered and developed by Theravance, Inc., and transferred to Theravance Biopharma, Inc. in connection with the separation of the two companies in June 2014. In May 2012, the European Commission suspended Marketing Authorization for VIBATIV(R) because the previous single-source drug product supplier did not meet the current Good Manufacturing Practice ("cGMP") requirements for the manufacture of VIBATIV(R). In March this year the European Commission reinstated the marketing authorisation for VIBATIV(R) as consistent product supply was re-established in accordance with European Commission requirements. Theravance Biopharma Antibiotics, Inc. has granted Clinigen exclusive commercialization rights to VIBATIV(R) in the EU and certain other European countries (including Switzerland and Norway). For further information, for healthcare professionals please visit www.vibativ.eu About Clinigen The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP). Clinigen share price is focused on acquiring its own intellectual property in licensed, niche, hospital-only critical care medicines, increasing the value of these medicines by developing new formulations and indications, then registering and marketing them in defined global markets. For more information, please visit www.clinigengroup.com Contact Details Clinigen Group plc Tel: +44 (0) 1283 495 010 Peter George, Group Chief Executive Officer Shaun Chilton, Chief Operating Officer Read Full Thread Follow Reply
08/9/2014 13:34	cestnous: The I. C. article; Buy ahead of Clinigen re-rating Bull points High margins Undervalued Experienced management Strong order book Bear points Lumpy revenue stream Disappointing 2013 After listing in late 2012, pharmaceutical group Clinigen (CLIN) fast become the darling of London’s junior Aim market. The listing price – 164p – surged to 690p early this year but some disappointments in half-year results in February led to a substantial share price fall. But with strong full-year numbers looking likely when the company reports its figures later this month, we think there is now considerable ground to make up on the upside. Investors therefore have a second opportunity to buy the stock, this time at a significant discount to 2013 levels. There are two main reasons Clinigen won rapturous support from investors when it arrived on the London Stock Exchange. The clinical trials market into which Clinigen supplies third-party material is growing at about 15 per cent a year. Secondly, Clinigen’s management had a proven track record in understanding the complex regulation surrounding specialist access to certain drugs – encompassed by its global access programme (GAP) division. But at the start of 2014, when Clinigen released half-year results for the six months to December, concerns started to build about the shares overheating. The clinical trial supply (CTS) division – responsible for more than 64 per cent of first-half sales – revealed a 13 per cent fall in sales to £39.5m, and it didn’t help that management admitted that a near four percentage point rise in the CTS gross profit margin – to 16.5 per cent – was ‘unsustainable’. Consequently, the shares crashed 17 per cent on the morning the news came out. But the company still holds substantial promise for future growth and increasing shareholder returns. The specialty pharmaceuticals division, which provides a solid backbone and accounted for just over half gross profits for the first six months of the year, is still in an early stage of development, with management aiming to add six new drugs over the next three to five years. Meanwhile, the CTS segment is forecast to grow 5 per cent in 2015, and GAP, which accounted for 16 per cent of first-half sales, continues to be Clinigen’s fastest-growing division. Encouragingly, chief executive Peter George says the lumpy nature of the CTS business and the drop in half-year sales was solely the result of strong comparative figures last year, which included a large number of low-margin anti-viral study sales. He also believes an overdependence on CTS revenues as the bulk of sales will soon be a thing of the past. A bullish trading update released at the end of July has already begun the re-rating of the stock. In it, Clinigen said it expects like-for-like sales growth of more than 7 per cent for 2014, with total revenues of no less than £126m. The GAP division is expected to report 50 per cent sales growth, and CTS should see revenues up more than 11 per cent in the second half compared with the first half. Continued improvement in gross margins across all the divisions also contributed to a 17 per cent improvement in underlying cash profits as at the end of June, suggesting full-year results should beat analysts’ expectations. Such a solid performance could be down to lower operational costs, and the keen prices paid for two newly acquired speciality pharma drugs: Cardioxane and Savene. And management says there is also potential in Clinigen’s new business pipeline for CTS and GAP, which broker N+1 Singer puts at about £200m. Come the 2014 annual results on 24 September, investors should glean further clarity on Clinigen’s new business pipeline and how the new speciality pharma products will help drive growth. This could provide the re-rating catalyst the stock needs. We think investors would do well to boost their stake in Clinigen while the shares trade on 16 times 2015 earnings. Buy. HR After losing its ‘hot stock’ status at the time of its half-year results in February, Clinigen looks set to re-rate Read Full Thread Follow Reply
01/3/2014 13:28	cestnous: Edison (paid for) research; Think it came out late last week. I'm out at the moment. Sorry about formatting. Clinigen is a research client of Edison Investment Resea r ch Limited Clinigen update Wednesday 26 February Buying opportunity Clinigen CLIN:LN 531p Mkt cap £438M Analyst: Franc Gregori We view the share price reaction down 17% at the time of writing as overdone , and believe current levels provide a great buying opportunity. Clinigen's share price has taken a pounding on the back of what is perceived as a poo r H1 result, raising fears t hat the company has already gone ex - growth. The reality is that Clinigen operates in very defensive specialist niches (mainly clinical trials supplies and access programmes for specialist products) that are not only grow ing organically but also benefi ting from greater out - sourcing of these non - core functions by the pharma majors. The reason for the disappointment is that sales in H1 were only up 6.5% (like for like) with underlying EPS up 7.8%. This is seen as poor for a company that is largely viewed as a growth story. If you want to set up a bear story , then it is quite easy:  Foscavir, a key product driver , is now ex - growth and will likely now grow in lin e with market demand (1 - 2% pa).  Clinical Trials Supply faces competitive pressures.  Global Access Pro grammes is see ing a large project terminate. However, t he facts are that the decline in revenue growth has been largely at the CTS business, where sales are down from £45.1m to £39.5m as a result of a de liberate policy of removing low - value contracts. This has resulted in the CTS gross profit rising by 12.4% to 16.5% y ear - o n - y ear . Ironically, last year the company was criticised for losing margin in this area. The performance elsewhere remains strong, with the points mentioned above already known and dealt with. As we look forward, we can see greater visibility on the programmes and contracts coming through, which should be enough to more than offset this decline. Read Full Thread Follow Reply
18/1/2013 09:30	cestnous: I.C. Today Clinigen delivers a profitable niche SHARE TIPS AND UPDATES Clinigen Group PLC (CLIN) SPECULATIVE HIGH RISK Bull points Unusual business model Absence of effective competitors Takes advantage of outsourcing trends Big customers set to sign up Bear points Customer base is narrow Premium rating for UK healthcare company Clinigen (CLIN) is that rare beast - a company whose share price performed well after flotation (for 164p in September). That made it the first successful healthcare flotation in the past five years. Now that the share price has settled, it is time to assess Clinigen's prospects in its niche area of global pharmaceuticals services. They look good. The company has grown quickly since its formation in 2010 and, while sales growth won't maintain the pace set in 2011 and 2012 (see table), lively organic growth should ensure that Clinigen's shares are good value for investors who want to diversify away from tired pharmaceuticals majors. Clinigen is an unusual company that specialises in supplying the drugs that big pharamceutical companies use in clinical trials. In addition, it takes on medicines that big pharma deems surplus to requirements and gives them a new lease of life. That makes it highly unusual as its nearest competitors are low-margin, capital-intensive wholesalers. Clinigen has found favour with pharma companies because wholesalers have a patchy record of preventing drugs for clinical trials from creeping onto the 'grey market' of parallel imports, where medicines are bought in cheap markets, repackaged and sold in higher-value countries. In Clinigen's case, excess drugs are destroyed and the company has no financial interest in finding a further buyer as it has already earned a fee from sourcing them. CLINIGEN ORD PRICE: 220p MARKET VALUE: £178m TOUCH: 217-220p 12-MONTH HIGH: 230p LOW:164p DIVIDEND YIELD: 1% PE RATIO: 13 NET ASSET VALUE: 36p NET CASH: £11.7m Year to 30 Jun Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p) 2010 21.3 1.23 - nil 2011 35.0 6.75 - nil 2012 82.1 15.8 14.5 nil 2013* 97.1 17.0 14.5 1.85 2014* 110.1 19.6 16.7 2.23 % change +13 +15 +15 +21 Normal market size: 3,000 Matched bargain trading *Numis forecasts (profits and earnings are not comparable with historic figures) NAV before placing; cash after placing Clinigen's rapid growth coincides with the prevailing trend for pharma companies to outsource more functions. Independent forecasters reckon that supplying drugs for trials in Europe and the US alone is worth £600m-£800m a year. And Clinigen estimates that the global market is worth about $2bn (£1.2bn). Regulators also help by prolonging the duration of trials, especially by insisting that new drugs must show tangible benefits over existing therapies. That means more trials using so-called comparator medicines. The most profitable part of Clinigen is its products business, which generates about 25 per cent of sales but more than 60 per cent of gross profits. The division looks to buy-in profitable drugs that have been deemed surplus to the requirements of big pharma companies. It has achieved notable success with AstraZeneca's HIV product, Foscavir. Clinigen's boffins added an indication to Foscavir for bone-marrow patients; its marketeers did a better job and sales more than quadrupled to £21.7m in response. Overall, Clinigen reckons it can generate a return on acquired medicines within two years. SHARE TIP SUMMARY: Clinigen's shares trade on 15 times current year forecasts from broker Numis. That puts them towards the top-end of valuations for healthcare companies in the UK. Investors may also be wary of Clinigen's reliance on just two customers for a large proportion of sales, though Novartis and Celgene are expected to sign up this year. Given that its services business is forecast to grow by 17 per a year over the next three years, they can probably live with those risks; especially as Clinigen has few tough competitors and has shown what it can do on its products side with Foscavir. Buy. Read Full Thread Follow Reply

Clinigen share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:31 V: D:20170925 00:54:06